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Abstract 
Objectives: Autism Spectrum Disorders (ASD) continue to be diagnosed at a rapidly 
progressing rate now estimated to be 1 in 91 children in the United States.  Autism is a pervasive 
developmental disorder characterized by a range of atypical behaviors that include difficulties 
with social reciprocity, impaired language development, resistance to change, and repetitive 
behaviors.  About 40-70% of children diagnosed with ASD suffer from gastrointestinal distress, 
impairing proper nutrient consumption, which has been associated with abnormalities in their 
intestinal microflora. The primary objective of the study was to quantify and compare both 
beneficial (Bifidobacteria, Lactobacilli) and pathogenic (Clostridia) bacteria in children aged 3-9 
with ASDs as compared to neurotypical controls.  Methods: Participants were selected based on 
the eligibility criteria prohibiting antibiotics or probiotics.  Molecular characterization of the 
stool samples included real-time polymerase chain reactions (PCR) assays for total 
Bifidobacterium, Lactobacillus, and Clostridium (C. clusters I, XIV, and C. bolteae).  
Results: Unpaired t-tests of the molecular characterization of ASD stool samples revealed 
significantly lower amounts of Lactobacilli (p = 0.0059) and higher amounts of C. bolteae (p = 
0.0079) than that of their typical peers.  No significant differences were found in the levels of 
Bifidobacteria (p=0.2066), C. cluster I (p = 0.9391), and C. cluster XIV (p = 0.187) between the 
two groups.  Conclusions: Results suggest that children with autism may have significantly 
lower amounts of beneficial (Lactobacilli) bacteria and higher amounts of pathogenic bacteria 
(C. bolteae).  Further study is warranted to determine whether interventions such as prebiotic or 
probiotic supplementation would be advantageous in improving intestinal microflora. 
 
Key words: autism, gastrointestinal microflora in autism, developmental disabilities
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CHAPTER 1  
INTRODUCTION 
1. Problem Statement 
Many parents of children with autism spectrum disorder (ASD) frequently report 
gastrointestinal distress in this population.  Children with autism may have insufficient amounts 
of beneficial intestinal microflora, which suggests excessive amounts of harmful microflora, 
compared to neurotypical children.  Understanding the composition of this population’s intestinal 
microflora may lead to improvements in the treatment of autism, as well as reveal information 
for further research in the field of autism. With estimates indicating 1 in 91 children are impacted 
by this disorder (1), this subject is of national importance. 
 
2. Review of Literature 
Autism: An Overview 
Autism spectrum disorder is a condition characterized by a range of atypical behaviors 
that include difficulties with social interactions, impaired language development, resistance to 
change, and repetitive behaviors.  Autism often creates an unstable and stressful environment for 
the affected child and his or her family members (2).  Although autism is characterized by a 
highly variable prognosis for children, “most children with an early diagnosis of autism are not 
completely independent as adults and the disorder generally has lifelong effects on the child’s 
ability to be social, to care for themselves, and to participate in the community (2).”  With no 
clear etiology, we are not equipped with effective means of prevention or treatments (2).  
Without a cure, we rely on the most recent research to lend insight into this increasingly 
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prevalent disorder so as to develop promising outcomes for the future of these affected children 
(2). 
It has been reported that many autistic children experience a variety of gastrointestinal 
disorders (3, 4).  Studies have revealed an abnormal composition of intestinal microflora in 
children with autism (2-7).  Of these studies examined, half of them documented the apparent 
association of the parallel onset of behavioral autistic symptoms with gastrointestinal 
complications (4-6, 8) as a result of the presence of compromised intestinal microflora (5, 6).  
These findings have provided a basis for further research into the connection among 
gastrointestinal complications, altered intestinal microflora, malabsorption, and the onset of 
behavioral characteristics of autism spectrum disorder in this population (9). 
Gastrointestinal Dysfunction and Behavioral Symptoms Manifested in Autism 
Many research articles have revealed gastrointestinal abnormalities in children diagnosed 
with autism spectrum disorder.   The symptoms reported include constipation, diarrhea, 
flatulence/bloating, gastroesophageal reflux, abdominal pain and gastrointestinal discomfort (5, 
8, 10).  Parents have noted the onset of behavior symptoms of autism and the above noted 
gastrointestinal complications to manifest themselves concurrently (4-6, 8), “however, until 
recently, gastrointestinal symptoms of these children received little attention (8, p. 560).”  
Almost twenty years after that publication, although many advances in this research field have 
been accomplished, we are still struggling to find the link between the gastrointestinal symptoms 
and ASD. 
Jyonouchi et al (10) investigated the relationship between an elimination diet (such as 
casein-free/gluten-free) and improvement in the gastrointestinal symptoms as well as apparent 
improvement of some behavioral symptoms of children with ASD.  They studied the association 
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of dietary proteins and innate immune response of 72 children with autism compared to children 
with dietary protein intolerances and unrelated healthy children.  Their results indicated an 
abnormal (inflammatory) innate immune response to dietary proteins play a role in 
gastrointestinal inflammation and subsequent gastrointestinal symptoms of ASD children.  
Furthermore, speculations that chronic gastrointestinal complications exacerbate some 
behavioral symptoms of autistic children, secondary to gastrointestinal discomfort, were revealed 
(10). 
Parracho et al (5) investigated the association of gastrointestinal problems and the 
indigenous gut flora of children with ASD.  Researchers disclosed that while “food intolerance is 
suspected to play a role in ASDs, the underlying cause of gastrointestinal symptoms remains 
unclear (5).”  The study found that gastrointestinal distress was associated with increased levels 
of clostridia, toxin-producing bacteria, in children with ASD.  Additionally, the study 
acknowledged the apparent worsening of behavioral symptoms during periods of gastrointestinal 
complications.  Researchers attributed this connection to the possible systemic effects of 
increased toxins, including neurotoxins, in the bloodstream from high levels of clostridia in the 
autistic gut (5). 
In a recently published medical hypothesis, Finegold reports that his review of literature 
suggests that “intestinal bacteria are a factor in autism in that autistic children showed 
improvement in behavior, communication, and social skills and in the gastrointestinal 
manifestations of their disease after oral vancomycin, an antibiotic that is essentially not 
absorbed from the gut (6),” was administered.  In fact, the researchers from this study, Sandler et 
al (11), found that eight of ten autistic children studied exhibited marked improvement during 
therapy.  However, “although improvement was clear by several measures (11),” the study 
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reported all but one autistic child regressed back towards baseline following the termination of 
the antibiotic.  Despite the fact that this study showed short-term improvement in behavioral 
autistic symptoms as a result of antibiotics not recommended for the treatment of autism, it has 
suggested a link between the gut flora and the brain activity of a subset of autistic children.  The 
investigators encouraged “further research of a possible gut-brain connection be vigorously 
pursued (11).” 
Intestinal Microflora Associated with Autism and its Significance 
After the link between autism and gastrointestinal complications was acknowledged as a 
key aspect of this idiopathic disorder, research began addressing the etiology of the 
gastrointestinal symptoms and their possible implications in autism spectrum disorder.  It was 
established early on that high frequencies of autistic children express altered (increased) gut 
permeability (4).  Researchers then developed interest in the composition of the intrinsic 
microflora of autistic children, providing the basis for current autism research (3, 5-7). 
Clostridia, a neurotoxin-producing, endospore-forming harmful bacterial species, have 
been documented to compromise the intrinsic microflora of autistic children compared to 
neurotypical children (3, 5-7, 11).  Furthermore, this organism is speculated to be responsible 
for, or at least contribute to the exacerbation of behavioral characteristics of autism (5, 6).    
Finegold et al published a study that revealed significantly higher counts and species of 
clostridia in the microflora of autistic children compared to those of neurotypical control children 
using traditionally cultured (plate-based method) specimens (7).  This group then produced a 
similar study, wherein they used real-time polymerase chain reaction (real-time-PCR) method 
due to the known limitations of significantly underestimating bacteria present in fecal samples 
using the traditional method (3).  Data collected in the latter study found that cell count 
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differences between the autistic and control children were statistically significant, revealing a 46-
fold elevation in Clostridia bolteae, a 9.0-fold elevation in Clostridia clusters I, and a 3.5-fold 
elevation in Clostridia clusters XI in autistic children compared to the control children (3).  Song 
et al (3) discuss the efficacy of real-time-PCR to reveal that “the findings in this study by real-
time PCR are in agreement with the previous observations and provide reliable quantitative 
information (3).”  The researchers then report that “investigation of the intestinal microflora is 
crucial for obtaining an understanding of the role of the gut microflora in health and also 
understanding the role of the microflora in disease (3).” 
Following these studies, Parracho et al recognized “numerical differences in gut flora of 
ASD patients and healthy subjects remain poorly studied (5),” and implemented their own 
investigation.  Their results indicated a significant relationship between autism and 
gastrointestinal symptoms.  Furthermore, those gastrointestinal complications were associated 
with increased levels of clostridia, suggesting an additional association with the development of 
certain autistic characteristics (5).  These findings support the integral role the gut microflora 
plays in autism (5).  Researchers suggest “modulation of the gut microflora by reducing the 
numbers of certain clostridia in ASD patients, while stimulating more beneficial gut bacteria, 
may help alleviate some of the related symptoms (5).” 
There is a clear implication throughout the literature of the importance of additional 
research in the field of autism to determine the role of gastrointestinal symptomatology and 
related autistic behaviors (9).  The prevalence of gastrointestinal symptomatology in children 
with ASD has a consensus of about 30-40%, with some estimates extending to 80% (9).  There 
are also speculated contributions of suboptimal gut microflora to these gastrointestinal 
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complications.  Geraghty et al (9) also describe the theory of altered intestinal permeability 
(“leaky gut”) which has been suggested to contribute to the characteristics of autism (9).   
Based on the information gathered from this preliminary study, future research may 
include the use of prebiotics and probiotics in children with autism.  These dietary supplements 
(prebiotics) promote the growth of the beneficial microorganisms, specifically, Bifidobacterium 
and Lactobacillus. The beneficial microorganisms are considered to have a protective effect on 
the gut integrity by preventing and inhibiting the growth of pathogenic bacteria (9).   
Conclusion 
Autism is a devastating disorder, not only to the children affected, but the parents and 
family members as well.  These children suffer from social and language skill deficits, as well as 
restrictive and repetitive patterns of activity.  With prevalence as high as 1 in 91, and no cure in 
sight, the need for research in this field is imperative. 
The gastrointestinal complications seen in autism have been associated with possibly 
affecting the development of certain autistic characteristics and behaviors.  These gastrointestinal 
symptoms have been linked to the compromised intestinal microflora of autistic children.  With 
the sophisticated techniques used in research these days, such as real-time polymerase chain 
reactions as well as the improved DNA extraction method published by Drs. Yu and Morrison 
(12), there is great potential for advancements in the understanding of and the treatment for 
children with autism spectrum disorder. 
Preliminary studies have obviated the necessity for further research into the connection 
between the autistic gut and the onset of autistic symptoms.  Research in this field may lead to 
discoveries related to the etiology of, symptoms related to, and potential treatments for autism 
spectrum disorders.  A recently developed research plan exhibits great potential for the future of 
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autistic children by embracing the already published knowledge, and implementing a plan to 
potentially correct the suboptimal gastrointestinal composition (13).  
Autism spectrum disorder is a multifactorial disorder not well understood, even today.  
However, as research advances, we may reveal knowledge that gives these children and families 
potential for a brighter future.   
 
3. Objectives 
The purpose of this study is intended to address two specific aims: 
 Specific Aim 1: To determine if lower quantities of beneficial microflora (Bifidobacteria 
and Lactobacilli) exists among children with autism spectrum disorder compared to 
neurotypical children, compromising the gut integrity of these individuals. 
 Specific Aim 2: To determine if higher quantities of pathogenic microflora (Clostridia) 
exists among children with autism spectrum disorder compared to neurotypical children, 
compromising the gut integrity of these individuals. 
Hypothesis: Children with autism spectrum disorder will possess significantly fewer counts 
of Bifidobacteria and Lactobacilli, and greater counts of the pathogenic family of bacteria, 
Clostridia, than those of neurotypical children. 
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CHAPTER 2 
METHODS AND MATERIALS 
This research is in conjunction with: Lane, A, Case-Smith, J, Geraghty, M. Factors 
predictive of problem eating behaviors in children with autism (IRB #2008H0315).  This study 
implemented consent-informed procedures as approved by the IRB in the OSU Office of 
Responsible Research Practices.  IRB approval dated February 16, 2009 has been obtained. 
1. Population and Sample 
Participants – Participants were selected based on a convenience sample for this pilot study.  
Thirteen children aged from 3 to 9 years diagnosed with autism spectrum disorder (includes: 
autism, Asperger’s syndrome, Pervasive Developmental Disorder (PDD) and Pervasive 
Developmental Disorder – Not Otherwise Specified (PDD-NOS)) were recruited to this pilot 
study.  An additional ten typically developing (neurotypical) children without immediate family 
members with any related ASD were recruited to compare intestinal microflora with children 
with autistic children. Eligibility criteria for all children prohibited the consumption of yogurt for 
the past (one) month, antibiotics for the past three months, and probiotic supplements for the past 
six months.  Neurotypical children were healthy and free of gastrointestinal diagnoses or 
symptoms. 
2. Design 
 
Recruitment Procedure – Eligible children with autism were recruited from relevant clinics at 
the Ohio State University Medical Center’s Nisonger Center and through established autism 
networks and support groups in Ohio.  Clinic coordinators at the Nisonger Center assisted in 
identifying eligible children.  Where the potential autistic child study participant is a past client 
of the clinic, families were mailed a letter of invitation to participate including information 
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about the study.  New clients presenting to the clinics were provided with study information by 
clinic coordinators once their eligibility had been determined.  IRB approved Informed Consent 
procedures and documents were employed.  Eligible neurotypical potential participants were 
recruited via OSU Child Care, broadcast emails to OSU faculty and staff, and personal contacts 
in Ohio.  
Study procedure – All neurotypical children and autistic participants were asked to supply a 
stool sample during an initial home visit.  An additional visit was scheduled to pick up and 
transfer the sample to a minus-eighty (-80 C) freezer as soon as possible so as to preserve the 
sample.  Participants were provided with a Stool kit, comprised of a fitted plastic toilet seat (in 
which to “catch” the specimen), a labeled 15 mL conical Falcon® tube in which to place the 
stool sample, plastic gloves, and a sterilized wooden mini-spatula. They were also provided with 
detailed stool collection instructions.  
This student’s (KK) role and responsibilities included: (1) recruitment of participants, (2) 
dropping off Stool kits and collecting stool samples from selected subjects at a time negotiated 
with the participants’ parent, (3) several hours of observing and aiding a lab assistant with DNA 
extraction and real-time polymerase chain reaction (real-time-PCR) method, and (4) collecting 
and analyzing data from the real-time-PCR assays.   
3. Methodology 
DNA extraction and real-time PCR assays.  Microbial community DNA was extracted from 0.5 
g of each stool sample using the repeated bead-beading +column (RBB+C) method, an improved 
method of DNA extraction published by Drs. Yu and Morrison, in whose lab we conducted our 
molecular work (12). The absolute abundance (AA) of Bifidobacteria, Lactobacilli, Clostridia 
Group I, Clostridia Group III and C. bolteae 16S rrs genes was quantified against each 
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respective standard using the group-specific real-time PCR assays. The relative abundance (RA) 
is expressed as the number of each group (or species) 16S rrs copies per million copies (cpmc) of 
total bacterial 16S RNA genes. The relative abundance was calculated by dividing the absolute 
abundance of each group (or species) by the total bacterial absolute abundance in each sample 
and then by multiplying by 1 million (RA = AA ÷ total bacterial AA X 1 million).  The primers 
and probes used in this study are listed in Table 1. Sample-derived standards were prepared for 
each real-time PCR assay using a composite DNA sample pooled from all the samples to be 
analyzed (14, 15).  The real-time PCR assays were carried out following the condition described 
previously (14, 15).  Total bacterial 16S rRNA genes were also quantified using a universal 
primer set and a universal TaqMan probe (14).  All the real-time PCR assays were done in 
triplicate for each standard and microbiome DNA sample. 
TABLE 1. Sequences of oligonucleotide primer and probes 
Target bacteria and probe or 
primer
a  Oligonucleotide sequence (5’3’)  
Amplicon 
size (bp) (°C)b
 
Probe-I 
6-FAM-5’- CGT ATT ACC GCG GCT GCT GGC 
AC-3’- TAMRA  70 
    
Bifidobacterium 
gBifid-F 
gBifid-R 
CTC CTG GAA ACG GGT GG 
GGT GTT CTT CCC GAT ATC TAC A 549-563 55°C 
    
Lactobacillus 
Lac1 
Lac2 
AGC AGT AGG GAA TCT TCC A 
ATT YCA CCG CTA CAC ATG 345  60°C 
    
Group I (Clostridium cluster I) 
CI-F1 
CI-R2 
TAC CHR AGG AGG AAG CCA C 
GTT CTT CCT AAT CTC TAC GCA T 232 63°C 
    
Group III (Clostridium cluster 
XIVab) 
CXIV-F1 
CXIV-R2 
GAW GAA GTA TYT CGG TAT GT 
CTA CGC WCC CTT TAC AC 150 52°C 
    
Probe-II (C. bolteae) 
C.bol-F 
C.bol-R 
CAG GTG GTG CAT GGT TGT CGT CAG 
CCT CTT GAC CGG CGT GT 
CCT AGA GTG CCC AGC TCT ACC TG 157 58°C 
14 
a
 Probe-I is an internal universal probe that corresponds to a region of the 16S rRNA gene that is conserved in 
all eubacteria (16); it was used with two sets of species (17, 18) and cluster-specific primers (3). Probe-II was 
used with C. bolteae-specific primer set (3). Clostridium clusters are as described in reference 19. 
b
 Primer annealing temp 
 
4. Data and Instrumentation 
Design – All neurotypical and autistic participants in this prospective, 2-visit, descriptive study 
were recruited according to IRB approved procedures mentioned above and asked to provide 
stool samples as described above under procedures. 
Instrumentation and Data Analysis – The collected stool samples underwent DNA extraction 
and real-time PCR in the Department of Animal Sciences, Drs. Yu and Morrison’s lab.  The 
extraction method used was developed by Drs. Yu and Morrison, and demonstrated to be an 
improved PCR-quality community DNA extraction has been published by the same OSU Animal 
Science group (12).  The molecular characterization of the stool samples determined quantifiable 
amounts of beneficial bacteria, Bifidobacterium and Lactobacillus, as well as the pathogenic 
bacteria, Clostridia (C. cluster I, C. cluster XIV, and C. bolteae), in both autistic children and 
neurotypical children.  Two-sample t-tests were used to determine whether differences existed in 
the five bacteria between the two groups of participants.  As stated in the hypotheses above, it 
was anticipated that less Bifidobacterium and Lactobacillus would be present in the ASD 
samples as compared to the controls whereas an elevation of Clostridia species was expected.  
One-sided tests were used to remain consistent with these hypotheses and a Bonferroni 
adjustment was used to protect Type I error.  The outcomes were log10-transformed to 
accommodate the assumptions of the tests, and analyzed by two-tailed unpaired t-tests 
(GraphPad Software, San Diego, CA).  Significance was declared at p ≤ 0.05.  
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CHAPTER 3 
RESULTS 
 Results are displayed as raw data expressed in relative abundance (Table 2) and means of 
real-time PCRs of each bacterial species characterized and analyzed (Figure 1 and 2).  
TABLE 2. Bacteria detection in stool samples of autistic and neurotypical control children by real-time PCR
a
 
Sample
b 
 
Bifidobacteria  Lactobacilli 
 Clostridia 
cluster I 
 Clostridia 
cluster XIV 
 Clostridia 
bolteae 
Neurotypical (n=10) 
 
  
  
 
 
 
 
 
 T05  4.16  0.97  3.16  5.45  2.85 
 T06  4.09  2.57  3.39  5.70  2.06 
 T07  4.29  2.72  3.42  5.42  2.16 
 T08  4.37  2.06  3.29  5.67  2.35 
 T09  4.05  2.03  3.52  5.38  2.20 
 T10  4.56  1.23  3.26  5.50  2.53 
 T11  5.13  1.57  3.48  5.41  2.25 
 T12  4.88  1.84  3.74  5.38  2.70 
 T13  4.20  0.88  3.33  5.34  2.21 
 T14  5.35  1.77  2.79  5.62  2.89 
           
Mean  SEM  4.5  0.15  1.76  0.12  3.34  0.079  5.49  0.04  2.42  0.09 
           
ASD (n=13)           
 A01  4.61  1.35  3.49  5.53  2.72 
 A02  4.72  0.47  2.38  5.08  3.10 
 A06  4.50  1.03  2.31  5.60  3.46 
 A07  4.35  0.97  4.66  5.77  3.65 
 A14  4.38  1.39  2.98  5.51  3.20 
 A17  3.90  1.54  3.42  5.37  2.82 
 A22  4.56  0.94  2.52  4.92  1.32 
 A28  4.51  1.13  4.25  5.39  2.39 
 A32  4.33  0.03  3.30  5.32  3.74 
 A33  4.75  0.98  3.81  5.10  3.53 
 A37  3.67  1.37  3.48  5.47  3.15 
 A38  3.78  1.82  3.19  4.99  3.91 
 A39  3.31  0.91  3.84  5.64  4.35 
            
Mean  SEM  4.26  0.12  1.07  0.13  3.36  0.19  5.36  0.07  3.18 0.21 
           
P value  0.2066  0.0059  0.9391  0.187  0.0079 
a 
Data expressed as relative abundance; copies per million copies (cpmc) of bacterial rrs genes; SEM, standard error of 
the mean. 
b 
T, neurotypical children; A, autistic children. 
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Specific Aim 1: When compared to neurotypical controls, children with ASD revealed 
significantly lower amounts of Lactobacilli (p = 0.0059).  No significant differences were found 
in the levels of Bifidobacetria (Figure 1). 
 
FIGURE 1. Means of real-time PCR of Bifidobacteria and Lactobacilli detected in stool samples 
of children with ASD compared to neurotypical controls.  P values of significance displayed. 
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Specific Aim 2: When compared to neurotypical controls, children with ASD revealed 
significantly higher amounts of C. bolteae (p = 0.0079).  No significant differences were found 
in the levels of C. cluster I and XIV (Figure 2). 
 
FIGURE 2. Means of real-time PCR of Clostridia species (C. cluster I, C. cluster XIV, C. 
bolteae) detected in stool samples of children with ASD compared to neurotypical controls. P 
values of significance displayed. 
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DISCUSSION 
The purpose of this study was to determine if the gut integrity of children with autism is 
compromised by a lower amount of beneficial microflora allowing for a higher amount of 
pathogenic microflora in the autistic gut.  This study aimed to reproduce results similar to that of 
the Song et al (3) study’s findings.  The study by Song et al (3) demonstrated the advantages of 
using real-time PCR in the molecular characterization of stool samples.  To our knowledge, this 
research team is the only group that also incorporated Drs. Yu and Morrison’s improved DNA 
extraction technique (12) as well as real-time PCR in the molecular characterization process.  
Analysis of the data collected from real-time PCR assays of children with autism 
compared to neurotypical controls suggest that children with autism may possess significantly 
lower counts of beneficial bacteria (Lactobacilli) and significantly higher counts of pathogenic 
bacteria (C. bolteae). No significant differences were found in the amounts of Bifidobacteria, C. 
cluster I, or C. cluster XIV.   
Limitations of this study include our small sample size (n=23), large age range (3-9), and 
difficulties obtaining age and gender-matched controls.  Although our eligibility criteria for 
neurotypical children included only children of normal health status and without gastrointestinal 
diagnoses or symptoms, there is no threshold or standard for the amount of beneficial or 
pathogenic bacteria known to inhabit the intrinsic microflora.  Thus, we are forced to use the gut 
microflora of neurotypical children, whether optimal or not is unknown, when comparing to 
autistic children. 
 Several reports document the apparent parallel onset of autistic symptoms with 
gastrointestinal complications (4-6, 8), which has been associated with abnormalities in their gut 
mucosa (5, 6).  The etiology of these abnormalities is not well understood in the literature today, 
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but it has been suggested that the imbalance of gastrointestinal microflora, or dysbiosis, in 
children with autism is related to autistic behaviors.  Some researchers suggest that the Clostridia 
species, neurotoxin-producing bacteria, are responsible for or at least contribute to exacerbation 
of autistic behaviors (5, 6).  Further research is necessary to determine the role that compromised 
gut integrity plays in autism spectrum disorders.   
A study by Sandler et al (11) found marked improvement in communication, social skills, 
behavior, and gastrointestinal manifestations in children with autism following short-term 
treatment with antibiotics; however, all but one autistic participant regressed towards baseline 
following termination of the treatment.  This suggests an even stronger link between the gut 
microflora and autistic symptoms (6).  Antibiotics are not indicated for use long term in this 
population due to obvious side effects.  This presents an indication for future research into the 
potential benefits of prebiotics and probiotics in this population.  These dietary supplements 
(prebiotics) feed the beneficial microflora.  When the beneficial bacteria ferment the 
fructooligosaccharides in prebiotics, it changes the pH of the intestinal track, making a very 
inhospitable environment for pathogenic bacteria (Clostridia) to thrive or survive.  Research into 
the potential beneficial effects of these dietary supplements in children with autism may shed 
insight into a proactive, long-term option for this population. 
Because the etiology of autism spectrum disorders remains unclear, we are not prepared 
with effective means of treatment or prevention.  The results of this research study support the 
theory that children with autism posses an imbalance of beneficial and pathogenic microflora in 
their gut mucosa.  Future studies with larger sample sizes as well as age and –gender matched 
controls are necessary to determine if compromised gut integrity exists among children with 
autism.  It would be worthwhile to have a retrospective questionnaire to determine if the autistic 
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child’s disorder arose in conjunction with gastrointestinal distress and/or complications.  
Understanding the role of dysbiosis in this population could lend to prospective approaches to 
this idiopathic disorder.  As the prevalence of autism continues to rise, research efforts must 
focus on the most promising solutions to accommodate these disorders.
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